Review



wild type mov10  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    OriGene wild type mov10
    Figure 1. Overexpression of <t>Mov10</t> decreases HIV-1 infectivity. (A) 293T cells were transfected with different amounts of Mov10 plasmid, and the expression of Mov10 was determined by Western blot. (B) 293T cells were transfected with 0.5 mg of either pCMV6-XL5 plasmid (control), Mov10 or APOBEC3G in the presence or absence of 0.5 mg vif as well as 1 mg HIV-1-GFP (Denv, Dvif, Dvpr, Dnef) and 0.5 mg p-L-VSV-G. Virus was collected 24 h later, and then added to Jurkat T cells. Virus transfer was standardized across treatment conditions by p24 levels as described (Materials and Methods). Percent infected cells was then determined using FACS analysis for GFP-expression after virus was allowed to incubate with target cells for 72 hours. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g001
    Wild Type Mov10, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pm20140200-146-0-10?v=OriGene
    Average 90 stars, based on 2 article reviews
    wild type mov10 - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity."

    Article Title: Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity.

    Journal: PloS one

    doi: 10.1371/journal.pone.0009081

    Figure 1. Overexpression of Mov10 decreases HIV-1 infectivity. (A) 293T cells were transfected with different amounts of Mov10 plasmid, and the expression of Mov10 was determined by Western blot. (B) 293T cells were transfected with 0.5 mg of either pCMV6-XL5 plasmid (control), Mov10 or APOBEC3G in the presence or absence of 0.5 mg vif as well as 1 mg HIV-1-GFP (Denv, Dvif, Dvpr, Dnef) and 0.5 mg p-L-VSV-G. Virus was collected 24 h later, and then added to Jurkat T cells. Virus transfer was standardized across treatment conditions by p24 levels as described (Materials and Methods). Percent infected cells was then determined using FACS analysis for GFP-expression after virus was allowed to incubate with target cells for 72 hours. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g001
    Figure Legend Snippet: Figure 1. Overexpression of Mov10 decreases HIV-1 infectivity. (A) 293T cells were transfected with different amounts of Mov10 plasmid, and the expression of Mov10 was determined by Western blot. (B) 293T cells were transfected with 0.5 mg of either pCMV6-XL5 plasmid (control), Mov10 or APOBEC3G in the presence or absence of 0.5 mg vif as well as 1 mg HIV-1-GFP (Denv, Dvif, Dvpr, Dnef) and 0.5 mg p-L-VSV-G. Virus was collected 24 h later, and then added to Jurkat T cells. Virus transfer was standardized across treatment conditions by p24 levels as described (Materials and Methods). Percent infected cells was then determined using FACS analysis for GFP-expression after virus was allowed to incubate with target cells for 72 hours. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g001

    Techniques Used: Over Expression, Infection, Transfection, Plasmid Preparation, Expressing, Western Blot, Control, Virus, Standard Deviation

    Figure 2. Mov10 decreases specific infectivity of HIV-1. Supernatants of 293T cells that had been transfected with varying amounts of Mov10- expressing plasmid were assayed for (A) HIV-1.Luc p24 levels and (B) after standardization by p24 content, infectivity of target cells was determined by luciferase activity from VSVG.HIV.Luc, which encodes all the HIV accessory genes. For simplicity, the amount of Mov10 plasmid that was transfected is expressed as a ratio of HIV-1 plasmid to Mov10 plasmid and plotted logarithmically. In the experiment (see Materials and Methods for further explanation) HIV-1 plasmid levels remained constant, while Mov10 plasmid was used at levels of 1/6 to 1/1500 that of the HIV-1 plasmid. Error bars represent one standard deviation. (C) Representative plots of Jurkat T cells infected with GFP-expressing virus produced in the presence of either pcDNA3 or Mov10 (ratio of Mov10 to HIV-1 plasmid was 1/25) three days after infection. Quantification of experiments performed using GFP- expressing virus is shown in supplemental figure 1. doi:10.1371/journal.pone.0009081.g002
    Figure Legend Snippet: Figure 2. Mov10 decreases specific infectivity of HIV-1. Supernatants of 293T cells that had been transfected with varying amounts of Mov10- expressing plasmid were assayed for (A) HIV-1.Luc p24 levels and (B) after standardization by p24 content, infectivity of target cells was determined by luciferase activity from VSVG.HIV.Luc, which encodes all the HIV accessory genes. For simplicity, the amount of Mov10 plasmid that was transfected is expressed as a ratio of HIV-1 plasmid to Mov10 plasmid and plotted logarithmically. In the experiment (see Materials and Methods for further explanation) HIV-1 plasmid levels remained constant, while Mov10 plasmid was used at levels of 1/6 to 1/1500 that of the HIV-1 plasmid. Error bars represent one standard deviation. (C) Representative plots of Jurkat T cells infected with GFP-expressing virus produced in the presence of either pcDNA3 or Mov10 (ratio of Mov10 to HIV-1 plasmid was 1/25) three days after infection. Quantification of experiments performed using GFP- expressing virus is shown in supplemental figure 1. doi:10.1371/journal.pone.0009081.g002

    Techniques Used: Infection, Transfection, Expressing, Plasmid Preparation, Luciferase, Activity Assay, Standard Deviation, Virus, Produced

    Figure 3. Mov10 impairs HIV-1 replication in primary CD4+ T cells. Supernatants of activated CD4+ cells that had been nucleofected with a replication competent, CCR5-tropic HIV-1 viral plasmid and either Mov10 or control (pcDNA3) plasmid ([A] schematic) were assayed for p24 production (B) and then standardized by p24 concentration and used to infect CCR5+ Hut cells. (C) Infection success was determined by flow cytometry analysis of GFP expression. doi:10.1371/journal.pone.0009081.g003
    Figure Legend Snippet: Figure 3. Mov10 impairs HIV-1 replication in primary CD4+ T cells. Supernatants of activated CD4+ cells that had been nucleofected with a replication competent, CCR5-tropic HIV-1 viral plasmid and either Mov10 or control (pcDNA3) plasmid ([A] schematic) were assayed for p24 production (B) and then standardized by p24 concentration and used to infect CCR5+ Hut cells. (C) Infection success was determined by flow cytometry analysis of GFP expression. doi:10.1371/journal.pone.0009081.g003

    Techniques Used: Plasmid Preparation, Control, Concentration Assay, Infection, Flow Cytometry, Expressing

    Figure 5. An optimal concentration of Mov10 is required for HIV-1 infectivity. 293T cells were transfected with a non-targeting siRNA or Mov10-specific siRNA. At 48 h post-siRNA transfection, the cells were transfected with 1.5 mg of pHIV-RFP, 0.7 mg of p-L-VSV-G and increasing amounts of the Mov10 expression plasmid. At 96 h post-siRNA transfection: (A) the cell lysates were examined by Western blot for Mov10 levels using an anti-Mov10 antibody. Equal protein loading was confirmed by probing with anti-tubulin antibody. (B) After normalizing for p24 values, virus obtained from the transfections was used to infect HeLa cells and infectivity was measured by FACS. The % infected cells represents the percentage of RFP-positive cells in the cell population. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g005
    Figure Legend Snippet: Figure 5. An optimal concentration of Mov10 is required for HIV-1 infectivity. 293T cells were transfected with a non-targeting siRNA or Mov10-specific siRNA. At 48 h post-siRNA transfection, the cells were transfected with 1.5 mg of pHIV-RFP, 0.7 mg of p-L-VSV-G and increasing amounts of the Mov10 expression plasmid. At 96 h post-siRNA transfection: (A) the cell lysates were examined by Western blot for Mov10 levels using an anti-Mov10 antibody. Equal protein loading was confirmed by probing with anti-tubulin antibody. (B) After normalizing for p24 values, virus obtained from the transfections was used to infect HeLa cells and infectivity was measured by FACS. The % infected cells represents the percentage of RFP-positive cells in the cell population. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g005

    Techniques Used: Concentration Assay, Infection, Transfection, Expressing, Plasmid Preparation, Western Blot, Virus, Standard Deviation

    Figure 4. Broad inhibition of infectious retroviruses by Mov10. Virions derived from 293T cells transfected with various viral plasmids (as described in Materials and Methods) and either pcDNA3 or pcDNA3- Mov10 were used to infect HeLa cells. The % infected cells represents the percentage of GFP-positive cells in the cell population. doi:10.1371/journal.pone.0009081.g004
    Figure Legend Snippet: Figure 4. Broad inhibition of infectious retroviruses by Mov10. Virions derived from 293T cells transfected with various viral plasmids (as described in Materials and Methods) and either pcDNA3 or pcDNA3- Mov10 were used to infect HeLa cells. The % infected cells represents the percentage of GFP-positive cells in the cell population. doi:10.1371/journal.pone.0009081.g004

    Techniques Used: Inhibition, Derivative Assay, Transfection, Infection

    Figure 6. Viral glycoprotein incorporation is not affected by Mov10 overexpression. 293T cells were transfected with plasmids necessary for the production of VSV-G pseudotyped Virion-Like Particles (VLPs) containing a GFP tag (as a Gag-GFP fusion) as well as either control or Mov10. Supernatant from these cells was then collected and added to Jurkat T cells and assayed for binding to target cells. Cells bound by one or more VLPs are GFP+ by FACS. doi:10.1371/journal.pone.0009081.g006
    Figure Legend Snippet: Figure 6. Viral glycoprotein incorporation is not affected by Mov10 overexpression. 293T cells were transfected with plasmids necessary for the production of VSV-G pseudotyped Virion-Like Particles (VLPs) containing a GFP tag (as a Gag-GFP fusion) as well as either control or Mov10. Supernatant from these cells was then collected and added to Jurkat T cells and assayed for binding to target cells. Cells bound by one or more VLPs are GFP+ by FACS. doi:10.1371/journal.pone.0009081.g006

    Techniques Used: Over Expression, Transfection, Control, Binding Assay

    Figure 7. Early and late reverse transcription is suppressed in virus produced from cells overexpressing Mov10. Synthesis of reverse transcripts by real-time PCR after infection by HIV-1 produced in the presence of either empty vector (pcDNA3) or Mov10 expressing plasmid was measured. No significant difference between production of (A) Early (R-U5) or (B) Late (R-Gag) DNA products of reverse transcription was observed. (C) Infectivity of virions produced in the presence of Mov10 was significantly inhibited. Input viruses were normalized for p24. Results are representative of one out of three similar experiments. doi:10.1371/journal.pone.0009081.g007
    Figure Legend Snippet: Figure 7. Early and late reverse transcription is suppressed in virus produced from cells overexpressing Mov10. Synthesis of reverse transcripts by real-time PCR after infection by HIV-1 produced in the presence of either empty vector (pcDNA3) or Mov10 expressing plasmid was measured. No significant difference between production of (A) Early (R-U5) or (B) Late (R-Gag) DNA products of reverse transcription was observed. (C) Infectivity of virions produced in the presence of Mov10 was significantly inhibited. Input viruses were normalized for p24. Results are representative of one out of three similar experiments. doi:10.1371/journal.pone.0009081.g007

    Techniques Used: Reverse Transcription, Virus, Produced, Real-time Polymerase Chain Reaction, Infection, Plasmid Preparation, Expressing

    Figure 8. The helicase domain of Mov10 is not required for HIV-1 restriction. Virions were produced by cotransfection of 293T cells with HIV-1 vector and either empty vector or Mov10, Mov10 N-terminus, Mov10 C-terminus or the putative helicase motif mutant expression plasmids. (A) Schematic of wild-type and mutated human Mov10 constructs. (B) Cell lysates were probed with anti-HA, anti-Mov10, and anti-tubulin. Lanes: 1) pcDNA3, 2) Mov10, 3) Mov10 Nterm, 4) Mov10 Cterm, and 5) Mov10-EQ. Arrows indicate molecular weight of native Mov10. (C) Infectivity of virions produced was examined by FACS after infection of HeLa cells. The % infectivity represents the percentage of RFP-positive cells in the cell population. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g008
    Figure Legend Snippet: Figure 8. The helicase domain of Mov10 is not required for HIV-1 restriction. Virions were produced by cotransfection of 293T cells with HIV-1 vector and either empty vector or Mov10, Mov10 N-terminus, Mov10 C-terminus or the putative helicase motif mutant expression plasmids. (A) Schematic of wild-type and mutated human Mov10 constructs. (B) Cell lysates were probed with anti-HA, anti-Mov10, and anti-tubulin. Lanes: 1) pcDNA3, 2) Mov10, 3) Mov10 Nterm, 4) Mov10 Cterm, and 5) Mov10-EQ. Arrows indicate molecular weight of native Mov10. (C) Infectivity of virions produced was examined by FACS after infection of HeLa cells. The % infectivity represents the percentage of RFP-positive cells in the cell population. Error bars represent one standard deviation. doi:10.1371/journal.pone.0009081.g008

    Techniques Used: Produced, Cotransfection, Plasmid Preparation, Mutagenesis, Expressing, Construct, Molecular Weight, Infection, Standard Deviation



    Similar Products

    94
    ATCC q836h4 unknown function ef 1098 duf898 family transmembrane protein 101 100 559 5 1e 73 q836l3 aall blastp
    Q836h4 Unknown Function Ef 1098 Duf898 Family Transmembrane Protein 101 100 559 5 1e 73 Q836l3 Aall Blastp, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pm40919784-204-245-277?v=ATCC
    Average 94 stars, based on 1 article reviews
    q836h4 unknown function ef 1098 duf898 family transmembrane protein 101 100 559 5 1e 73 q836l3 aall blastp - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    99
    Cytiva Europe protein g functionalized chip
    Protein G Functionalized Chip, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pmc12560131__se5c02450_si_001-35-29-33?v=Cytiva+Europe
    Average 99 stars, based on 1 article reviews
    protein g functionalized chip - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    86
    Stryker dead box protein functions
    Dead Box Protein Functions, supplied by Stryker, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pm41879378-500-14-7?v=Stryker
    Average 86 stars, based on 1 article reviews
    dead box protein functions - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Staples mrnip protein function
    Mrnip Protein Function, supplied by Staples, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pm41491062-56-0-17?v=Staples
    Average 86 stars, based on 1 article reviews
    mrnip protein function - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Cold Spring Harbor Laboratory Meetings sir2 proteins function
    Sir2 Proteins Function, supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/us12485135-30-12-42?v=Cold+Spring+Harbor+Laboratory+Meetings
    Average 86 stars, based on 1 article reviews
    sir2 proteins function - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc protein function
    Protein Function, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pmc12592524-23-35-40?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    protein function - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc multiple protein functions
    Multiple Protein Functions, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pmc12664516-28-18-29?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    multiple protein functions - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    86
    Invitae Inc slc6a19 protein function
    The 9 missense mutations do not co-localize with the plasma membrane marker. (A) B0AT1-WT shows plasma membrane localization. (B–J) Immuno-cytochemistry images of B0AT1 mutants <t>(SLC6A19)</t> localization; Immuno-cytochemistry images of B0AT1 with single nucleotide generated via site directed mutagenesis. These mutants show no normal localization, without co-localization with the PM marker GFP-hRas. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.
    Slc6a19 Protein Function, supplied by Invitae Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/protein+function/pmc12368292-244-13-0?v=Invitae+Inc
    Average 86 stars, based on 1 article reviews
    slc6a19 protein function - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    Image Search Results


    The 9 missense mutations do not co-localize with the plasma membrane marker. (A) B0AT1-WT shows plasma membrane localization. (B–J) Immuno-cytochemistry images of B0AT1 mutants (SLC6A19) localization; Immuno-cytochemistry images of B0AT1 with single nucleotide generated via site directed mutagenesis. These mutants show no normal localization, without co-localization with the PM marker GFP-hRas. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Hartnup disease-causing SLC6A19 mutations lead to B0AT1 aberrant trafficking and ACE2 mis-localisation implicating the endoplasmic reticulum protein quality control

    doi: 10.3389/fcell.2025.1589534

    Figure Lengend Snippet: The 9 missense mutations do not co-localize with the plasma membrane marker. (A) B0AT1-WT shows plasma membrane localization. (B–J) Immuno-cytochemistry images of B0AT1 mutants (SLC6A19) localization; Immuno-cytochemistry images of B0AT1 with single nucleotide generated via site directed mutagenesis. These mutants show no normal localization, without co-localization with the PM marker GFP-hRas. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.

    Article Snippet: Invitae Labs also reports that this missense variant is not expected to disrupt SLC6A19 protein function, PolyPhen predicts it to be “benign (0.24)”.

    Techniques: Clinical Proteomics, Membrane, Marker, Immunocytochemistry, Generated, Mutagenesis, Immunofluorescence

    The 9 missense mutations co-localize with the ER marker. (A) B0AT1-WT shows plasma membrane localization with no ER retention. (B–J) Immuno-cytochemistry images of B0AT1 mutants (SLC6A19) generated via site-directed mutagenesis. The mutants show ER retention, confirmed by co-localization with Calnexin (an ER marker), while H-Ras serves as the plasma membrane marker. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Hartnup disease-causing SLC6A19 mutations lead to B0AT1 aberrant trafficking and ACE2 mis-localisation implicating the endoplasmic reticulum protein quality control

    doi: 10.3389/fcell.2025.1589534

    Figure Lengend Snippet: The 9 missense mutations co-localize with the ER marker. (A) B0AT1-WT shows plasma membrane localization with no ER retention. (B–J) Immuno-cytochemistry images of B0AT1 mutants (SLC6A19) generated via site-directed mutagenesis. The mutants show ER retention, confirmed by co-localization with Calnexin (an ER marker), while H-Ras serves as the plasma membrane marker. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.

    Article Snippet: Invitae Labs also reports that this missense variant is not expected to disrupt SLC6A19 protein function, PolyPhen predicts it to be “benign (0.24)”.

    Techniques: Marker, Clinical Proteomics, Membrane, Immunocytochemistry, Generated, Mutagenesis, Immunofluorescence

    ER-retained B0AT1 variants and ACE2 co-transfection with GFP-hRas in Hela cells. (A) Co-localization of WT-ACE2 (Blue) with the plasma membrane marker GFP-hRas (Green). (B–J) Co-localization of ER-retained B0AT1 (SLC6A19) mutants (Red) and WT-ACE2 (Blue) Immuno-cytochemistry show the of B0AT1 mutants on ACE2 localization. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Hartnup disease-causing SLC6A19 mutations lead to B0AT1 aberrant trafficking and ACE2 mis-localisation implicating the endoplasmic reticulum protein quality control

    doi: 10.3389/fcell.2025.1589534

    Figure Lengend Snippet: ER-retained B0AT1 variants and ACE2 co-transfection with GFP-hRas in Hela cells. (A) Co-localization of WT-ACE2 (Blue) with the plasma membrane marker GFP-hRas (Green). (B–J) Co-localization of ER-retained B0AT1 (SLC6A19) mutants (Red) and WT-ACE2 (Blue) Immuno-cytochemistry show the of B0AT1 mutants on ACE2 localization. Immunofluorescence images were captured with a Nikon eclipse i80 at magnification of ×100. Scale bar = 50 μm.

    Article Snippet: Invitae Labs also reports that this missense variant is not expected to disrupt SLC6A19 protein function, PolyPhen predicts it to be “benign (0.24)”.

    Techniques: Cotransfection, Clinical Proteomics, Membrane, Marker, Immunocytochemistry, Immunofluorescence